Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease.
Journal
Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
01
03
2019
revised:
11
08
2019
accepted:
12
08
2019
pubmed:
16
8
2019
medline:
9
4
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
To longitudinally evaluate the role of depression in the development of impulse control disorders (ICDs) in Parkinson disease (PD) patients. Using data from the Parkinson's Progression Markers Initiative, we included PD patients without ICDs at baseline according to the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP). Patients were prospectively evaluated first quarterly and then biannually. Development of an ICD was defined as an increase in QUIP scores during follow-up. Using survival proportional hazard models, we studied the effect of baseline depression on ICD risk. We also evaluated this effect controlling for dopamine agonist use as a time-dependent variable and for other potential confounders. Among 354 patients, 68 were depressed at baseline. The median follow-up was 4.08 years. Depression at baseline was associated with higher ICD risk (hazard ratio [HR] = 1.96, 95% confidence interval [CI] = 1.32-2.9, p < 0.001). This risk remained significant after controlling for dopamine agonist use (HR = 1.97, 95% CI = 1.33-2.9, p < 0.001), which was also independently linked to ICD development (HR = 1.87, 95% CI = 1.3-2.7, p < 0.001). Therefore, depressed patients faced an even higher ICD risk when receiving dopamine agonists. Controlling for multiple potential confounders did not alter these results. Depression predisposes to the development of ICDs in PD. This risk is magnified by dopamine agonists. Dopamine agonists should thus be used cautiously in depressed PD patients. ANN NEUROL 2019;86:762-769.
Substances chimiques
Dopamine Agonists
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
762-769Subventions
Organisme : Health Research Fund of the Ministry of Health and Consumer Affairs
ID : PI15/00962
Pays : International
Organisme : TV3 Marathon
ID : 20142910
Pays : International
Organisme : TV3 Marathon
ID : 2014/U/477
Pays : International
Organisme : Center for Biomedical Research on Neurodegenerative Diseases
Pays : International
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 American Neurological Association.
Références
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406.
Reijnders JSAM, Ehrt U, Weber WEJ, et al. A systematic review of prevalence studies of depression in Parkinson's disease: the prevalence of depression in PD. Mov Disord 2008;23:183-189.
Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord 2013;28:327-333.
Corvol J-C, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91:e189-e201.
Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008;23:1889-1896.
Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009;24:2175-2186.
Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006;113:211-220.
Weintraub D, Papay K, Siderowf A, et al. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 2013;80:176-180.
Weintraub D. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.
Joutsa J, Martikainen K, Vahlberg T, et al. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord 2012;18:155-160.
Callesen MB, Weintraub D, Damholdt MF, Møller A. Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: prevalence, depression, and personality. Parkinson Relat Disord 2014;20:22-26.
Goerlich-Dobre KS, Probst C, Winter L, et al. Alexithymia-an independent risk factor for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2014;29:214-220.
Pettorruso M, Fasano A, De Risio L, et al. Punding in non-demented Parkinson's disease patients: relationship with psychiatric and addiction spectrum comorbidity. J Neurol Sci 2016;362:344-347.
Weintraub D, Mamikonyan E, Papay K, et al. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord 2012;27:242-247.
Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-580.
Samuel M, Rodriguez-Oroz M, Antonini A, et al. Impulse control disorders in Parkinson's disease: management, controversies, and potential approaches. Mov Disord 2015;30:150-159.
Lorains FK, Cowlishaw S, Thomas SA. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction 2011;106:490-498.
de Jonge P, Alonso J, Stein DJ, et al. Associations between DSM-IV mental disorders and diabetes mellitus: a role for impulse control disorders and depression. Diabetologia 2014;57:699-709.
Brown RA, Lewinsohn PM, Seeley JR, Wagner EF. Cigarette smoking, major depression, and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1602-1610.
Boden JM, Fergusson DM. Alcohol and depression. Addiction 2011;106:906-914.
Marek K, Jennings D, Lasch S, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635.
Kraemmer J, Smith K, Weintraub D, et al. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry 2016;87:1106-1111.
Rutten S, van der Ven PM, Weintraub D, et al. Predictors of anxiety in early-stage Parkinson's disease-results from the first two years of a prospective cohort study. Parkinsonism Relat Disord 2017;43:49-55.
Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009;24:1461-1467.
Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item Geriatric Depression Scale and Hamilton Depression Rating Scale in Parkinson disease. Am Jf Geriatr Psychiatry 2006;14:169-175.
Torbey E, Pachana NA, Dissanayaka NNW. Depression rating scales in Parkinson's disease: a critical review updating recent literature. J Affect Disord 2015;184:216-224.
Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 2003;327:1144-1146.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
Spielberger CD. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Mind Garden, 1983.
Mondolo F, Jahanshahi M, Granà A, et al. Evaluation of anxiety in Parkinson's disease with some commonly used rating scales. Neurol Sci 2007;28:270-275.
Stiasny-Kolster K, Mayer G, Schäfer S, et al. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007;22:2386-2393.
Nomura T, Inoue Y, Kagimura T, et al. Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. Sleep Med 2011;12:711-713.
Snapinn SM, Jiang Q, Iglewicz B. Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator. Am Stat 2005;59:301-307.
Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(suppl 3):S42-S80.
Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 2015;69:183-189.
Marín-Lahoz J, Pagonabarraga J, Martinez-Horta S, et al. Parkinson's disease: impulsivity does not cause impulse control disorders but boosts their severity. Front Psychiatry 2018;9:465.
Gentile DA, Choo H, Liau A, et al. Pathological video game use among youths: a two-year longitudinal study. Pediatrics 2011;127:e319-e329.
Martinez-Martin P, Leentjens AFG, de Pedro-Cuesta J, et al. Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. Mov Disord 2016;31:270-279.
Slinker BK. The statistics of synergism. J Mol Cell Cardiol 1998;30:723-731.
Rektorová I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.
Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord 2019;34:180-198.
Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci. 2017;18:741-752.
Aracil-Bolaños I, Strafella AP. Molecular imaging and neural networks in impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2016;22(suppl 1):S101-S105.
Aarsland D, Påhlhagen S, Ballard CG, et al. Depression in Parkinson disease-epidemiology, mechanisms and management. Nat Rev Neurol 2012;8:35-47.
Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci 2013;14:609-625.
Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 2011;12:623-637.
Nestler EJ. Role of the brain's reward circuitry in depression: transcriptional mechanisms. Int Rev Neurobiol 2015;124:151-170.
Cowen PJ. Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci 2008;29:433-436.
Lee J-Y, Jeon BS, Kim H-J, Park S-S. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat Disord 2012;18:76-78.
Polter AM, Kauer JA. Stress and VTA synapses: implications for addiction and depression. Eur J Neurosci 2014;39:1179-1188.